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Background/Aims: We assessed changes in hemodynamic and arterial stiffness parameters following reductions of 
dialysate calcium concentrations in patients undergoing hemodialysis.
Methods: In this prospective study, 20 patients on maintenance hemodialysis (10 females, 10 males) with dialysate 
calcium concentrations of 1.75 mmol/L were enrolled. At the start of the study, the dialysate calcium level was lowered 
to 1.50 mmol/L. Serial changes in biochemical, hemodynamic, and arterial stiffness parameters, including pulse wave 
velocity (PWV) and augmentation index (AIx), were assessed every 2 months for 6 months. We also examined changes in 
the calcification-inhibitory protein, serum fetuin-A. 
Results: During the 6-month study period, serum total calcium and ionized calcium decreased consistently (9.5 ± 1.0 to 
9.0 ± 0.7, p = 0.002 vs. 1.3 ± 0.1 to 1.1 ± 0.1, p = 0.035). Although no apparent changes in blood pressure were observed, 
heart-femoral PWW (hf-PWV) and AIx showed significant improvement (p = 0.012, 0.043, respectively). Repeated-
measures ANOVA indicated a significant effect of lowering dialysate calcium on hf-PWV (F = 4.58, p = 0.004) and AIx (F 
= 2.55, p = 0.049). Accompanying the change in serum calcium, serum fetuin-A levels significantly increased (95.8 ± 45.8 
pmol/mL at baseline to 124.9 ± 82.2 pmol/mL at 6 months, p = 0.043). 
Conclusions: Lowering dialysate calcium concentration significantly improved arterial stiffness parameters, which may 
have been associated with upregulation of serum fetuin-A.
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IntRoDuCtIon
Arterial stiffness and vascular calcification are common 
findings in patients with end-stage renal disease (ESRD), 
and they contribute to the development and progression of 
cardiovascular complications [1-3]. Although the precise 
pathophysiological mechanisms of arterial stiffness and 
vascular calcification are not yet fully understood, passive 
calcium deposition and active modification of osteotro-
phic regulators such as osteoprotegerin and fetuin-A are 
thought to play important roles in this process [4-6].
Because the diffusion of calcium during hemodialysis 
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depends on the gradient between serum and dialysate 
calcium concentrations [7-9], understanding the effects 
of lowering dialysate calcium concentrations in patients 
undergoing hemodialysis is important. To date, several 
studies have examined the complex relationships among 
serum calcium levels, the degree of vascular calcification, 
and arterial stiffness in patients with ESRD, and low cal-
cium dialysate has been reported to reduce serum calcium 
levels, which is helpful in improving arterial stiffness 
[10,11]. However, these studies were relatively short-term 
trials and did not demonstrate serial changes in arterial 
stiffness. Moreover, no reported study has evaluated the 
relationship between serum calcium concentrations and 
changes in serum fetuin-A, a calcification-inhibitory pro-
tein.
In this study, we prospectively evaluated changes in 
hemodynamic and arterial stiffness parameters, includ-
ing pulse wave velocity (PWV) and augmentation index 
(AIx), after lowering dialysate calcium concentrations for 
6 months in patients on hemodialysis. Changes in serum 
fetuin-A levels were also examined.
MetHoDS
This was a single-center, prospective observational 
study performed at Gangnam Severance Hospital in Seoul, 
Korea, from December 2008 to July 2009. The inclusion 
criteria were patients between 20 and 80 years of age who 
had been on regular hemodialysis (three or four times 
per week) with a high dialysate calcium concentration 
(1.75 mmol/L) for at least 6 months. We excluded patients 
with a history of recent hospitalization for cardiovascular 
events, acute or chronic inflammation, or parathyroidec-
tomy. In total, 20 clinically stable patients on hemodialysis 
were enrolled. 
The study was approved by the Institutional Review 
Board for Human Research at Yonsei University College 
of Medicine. Informed consent was obtained from all pa-
tients.
Biochemical and hemodynamic data were obtained 
at baseline. Total calcium, ionized calcium, phosphorus, 
serum creatinine, albumin, intact parathyroid hormone 
(PTH), and C-reactive protein levels were checked under 
standardized fasting conditions immediately before the 
start of dialysis sessions. Using an automatic blood pres-
sure monitor device, blood pressure was measured in the 
resting state before (pre-dialysis) and after (post-dialysis) 
each session. The mean value of three consecutive mea-
surements was used. Arterial stiffness parameters (PWV, 
AIx) were measured after dialysis in the resting state. 
After the baseline measurement, the dialysate calcium 
concentration was lowered, from 1.75 to 1.5 mmol/L, and 
this change was maintained for 6 months. Blood samples 
were taken and arterial stiffness parameters were checked 
every 2 months. In total, four blood tests and arterial stiff-
ness measurements were taken during the 6 months (T0, 
T2month, T4month, and T6month).
Blood samples were also obtained for assessment of se-
rum fetuin-A levels. Serum fetuin-A levels were checked 
twice, at baseline and at the end of the study (T0 and 
T6month). To assess serum fetuin-A, the collected blood sam-
ples were immediately centrifuged (5,000 g, 10 minutes) 
and then stored at -70°C until the assays were performed. 
A commercially available enzyme-linked immunosorbent 
assay (ELISA) kit (DuoSet ELISA Development kit, R&D 
Systems, Minneapolis, MN, USA) was used. Intra- and 
inter-assay coefficients of variation were less than 10%. In 
each subject, two sequences of measurements were per-
formed and their mean value was used for the statistical 
analysis.
To assess additional calcium sources, a complete medi-
cation list, including calcium-containing phosphate bind-
ers and vitamin D agents, was reviewed. Adverse events, 
including hypotension and muscle cramps, were surveyed 
during the study period.
Assessment of arterial stiffness parameters
PWV and AIx were assessed using an automated device 
(VP-2000; Colin Co. Ltd., Komaki, Japan). Measurements 
were performed according to manufacturer instructions 
by the same physician 15 minutes after each midweek di-
alysis session with the patient in a resting, supine position.
The automatic device simultaneously obtains electrocar-
diograms, phonocardiograms, bilateral brachial and ankle 
blood pressures, and carotid and femoral arterial pulse 
waves. The PWV was determined from measurements of 
pulse transit time and the distance in the heart-femoral 
(hf) and brachial-ankle (ba) segments. The hf-PWV was 
considered to represent the central PWV. AIx was deter-
mined by automatic identification of the inflection point 
on the carotid pulse wave by applanation tonometry. It 
322    The Korean journal of Internal medicine Vol. 26, No. 3, September 2011
http://dx.doi.org/10.3904/kjim.2011.26.3.320 http://www.kjim.or.kr
was calculated by dividing the augmented pressure ampli-
tude (the difference between early and late systolic peaks) 
by the pulse pressure and expressed as a percentage. In 
younger subjects, aortic AIx is close to zero or may have a 
negative value. With aging, the aorta stiffens and the value 
becomes positive. The maximum value of AIx is approxi-
mately 50%.
Data analysis
Statistical analyses were performed using the SPSS ver-
sion 15.0 (SPSS Inc., Chicago, IL, USA). All values are ex-
pressed as means ± standard deviation or as a percentage 
(%). Serial changes in each parameter during the 6-month 
follow-up were analyzed by Wilcoxon’s signed-rank test 
and repeat-measure ANOVA. Because two patients were 
lost at 5 months (one died and one was transferred to a 
private clinic), final measurements for these patients were 
analyzed using last observation carried forward methods. 
Correlations among percentage change in serum calcium 
level, arterial stiffness parameters, and fetuin-A were de-
termined by Spearman’s correlation analysis. p values < 
0.05 were considered to indicate statistical significance.
ReSuLtS 
Baseline characteristics
In total, 20 maintenance hemodialysis patients partici-
pated in this study. The baseline clinical characteristics 
of the patients are outlined in Table 1. The mean age was 
62.5 ± 12.4 years and the median duration of hemodialysis 
was 37.8 months (range, 19 to 56). The patients consisted 
of 10 females and 10 males and the most common cause 
of ESRD was diabetes mellitus (n = 15, 75%). At the be-
ginning of the study, 45% (n = 9) of patients were taking 
calcium-based phosphate binders (calcium acetate), 30% 
(n = 6) were taking non-calcium-based phosphate binders, 
and the remaining patients took no phosphate binder. No 
patient was on active vitamin D therapy. Antihypertensive 
medications at baseline included angiotensin-converting 
enzyme or angiotensin II receptor blockers in 90%, calci-
um channel blockers in 65%, β-blockers in 50%, and other 
medications in 10%.
Changes in clinical and biochemical parameters 
during 6 months
The effects of reducing dialysate calcium on clinical and 
biochemical parameters are listed in Table 2. No signifi-
cant change occurred in body weight, ultrafiltration rate, 
or adverse event rate during hemodialysis. After lowering 
dialysate calcium, serum total calcium levels decreased 
significantly, from 9.5 ± 1.0 mg/dL at baseline to 9.0 ± 0.7 
mg/dL at 6 months (p = 0.031), and serum ionized calcium 
levels also decreased, from 1.3 ± 0.1 mmol/L to 1.1 ± 0.1 
mmol/L (p = 0.001). Serum phosphorus levels increased 
significantly (4.8 ± 1.2 at baseline vs. 5.6 ± 1.5 at 6 months; 
p = 0.025), and serum intact PTH levels increased gradu-
ally, from 80.6 ± 51.7 pg/mL at baseline to a maximum 
of 253.8 ± 160.9 pg/mL at 4 months (p < 0.001). At this 
point, active vitamin D treatment was administered to 
five patients to prevent secondary hyperparathyroidism 
table 1. Baseline demographic and clinical 
characteristics of the subjects (n = 20)
Variables Values 
Age, yr 62.5 ± 12.4
Gender, male    10 (50.0)
Dialysis duration, mona    37.8 (19-56)
History of cardiovascular disease    13 (65.0)
Causes of end-stage renal disease
Diabetes mellitus    15 (75.0)
Hypertension      4 (20.0)
Glomerulonephritis    1 (5.0)
Phosphate binder
   Calcium-based      9 (45.0)
   Non-calcium-based      6 (30.0)
   No use      5 (25.0)
medication of hypertension
   ARB 14 (70.0)
   ACEi   4 (20.0)
   Calcium channel blocker 13 (65.0)
   Beta blocker 10 (50.0)
   Others   2 (10.0)
Ultrafiltration volume, mL 2,110 ± 1,175
Daily urine output, mL/day 160.5 ± 61.3
spKT/V    1.15 ± 0.31
Values are presented as mean ± SD, number (%) or median 
(range). ARB, angiotensin II receptor blocker; ACEi, angiotensin-
converting enzyme inhibitor.
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and the intact PTH level decreased thereafter to 137.0 ± 
79.4 pg/mL at 6 months; however, the difference was still 
significant (p = 0.001). No significant change was observed 
in hemoglobin, calcium-phosphorus product, glucose, uric 
acid, total cholesterol, or C-reactive protein levels over the 
study period.
Changes in hemodynamic and arterial stiffness 
parameters and fetuin-A
No apparent change was detected in systolic, diastolic, 
mean arterial blood pressure, or pulse pressure during 
follow-up (Table 3). However, hf-PWV and heart rate-ad-
justed AIx showed significant improvements (1,548 ± 450 
cm/sec, 23.3 ± 17.5%, at baseline vs. 1,288 ± 345 cm/sec, 
15.2 ± 19.0% at 6 months; p = 0.012, 0.043, respectively).
Moreover, accompanying the changes in serum calcium 
levels, serum fetuin-A levels increased significantly, from 
95.8 ± 45.8 pmol/mL at baseline to 124.9 ± 82.2 pmol/
mL at 6 months (p = 0.043; Fig 1). A negative and signifi-
cant correlation was detected between serum calcium and 
fetuin-A level (r = -0.52, p = 0.027 at 6 months).
Reduction in serum calcium and its relationship 
with arterial stiffness markers
The percentage change in serum calcium level (∆serum 
calcium, %) was significantly correlated with the change 
in post-dialysis hf-PWV (∆hf-PWV, r = 0.721, p < 0.001) 
and the serum fetuin-A level (∆fetuin-A; r = -0.463, p = 
0.046; Fig. 2). Further analysis, using repeated-measures 
ANOVA, confirmed the significant effect of lowering dialy-
sate calcium on hf-PWV (F = 4.58, p = 0.004) and heart 
rate-adjusted AIx (F = 2.55, p = 0.049).
DISCuSSIon
Arterial stiffness is an important manifestation of 
vascular calcification. Although vascular calcification is 
thought to result from old age and atherosclerosis, not all 
vascular calcification occurs in the presence of atheroscle-
rosis. Previously, physicochemical factors alone, such as 
calcium-phosphate derangement and alkaline pH, were 
thought to regulate the development of vascular calcifica-
tion. However, recent studies have demonstrated that it is 
an elaborately regulated process, involving bone morpho-
genic proteins including osteoprotegerin and fetuin-A, and 
table 2. Clinical and biochemical data at baseline and 6 months after reducing dialysate calcium concentration 
(1.75 → 1.5 mmol/L)
Parameters Baseline 2 mon 4 mon 6 mon
Body weight, kg    55.0 ± 13.6    57.4 ± 13.1   57.1 ± 11.1    57.0 ± 12.6
Ultrafiltration volume, kg    2.5 ± 0.1    2.7 ± 1.4   2.7 ± 0.7   2.8 ± 1.5
Adverse eventsa, n    5    7   5 6
Hemoglobin, g/dL  10.8 ± 1.0   11.0 ± 2.5 10.9 ± 1.3 10.3 ± 0.6
Creatinine, mg/dL 9.8 ± 4.6 9.8 ± 4.8    9.8 ± 4.2    9.7 ± 5.2
Total calcium, mg/dL 9.5 ± 1.0 9.2 ± 0.1    9.1 ± 1.2     9.0 ± 0.7b
Ionized calcium, mmol/L 1.3 ± 0.1 1.2 ± 0.2   1.2 ± 0.1     1.1 ± 0.1c
Phosphorus, mg/dL  4.8 ± 1.2 4.9 ± 1.3   5.4 ± 1.7     5.6 ± 1.5b
Ca × P product, mg2/dL2    44.0 ± 12.4     47.1 ± 15.6   49.5 ± 17.3   49.6 ± 13.7
Intact PTH, pg/dL    80.6 ± 51.7  166.4 ± 81.8    253.8 ± 160.9c  137.0 ± 79.4c
Glucose, mg/dL   110.4 ± 41.9  108.9 ± 43.7  128.5 ± 38.0  114.8 ± 39.9
Uric acid, mg/dL    6.4 ± 1.1    6.6 ± 1.4   6.8 ± 1.7 6.80 ± 1.5
Total cholesterol, mg/dL  155.1 ± 31.6  153.9 ± 32.1 158.7 ± 41.1    156.1 ± 35.89
Albumin, g/dL    3.9 ± 0.4    3.7 ± 1.0   3.7 ± 0.9   4.1 ± 0.1
C-reactive protein, mg/L    2.2 ± 1.7    2.0 ± 2.3    2.1 ± 2.5   2.3 ± 3.5
Ca, calcium; P, phosphorus; PTH, parathyroid hormone.
aAdverse events include intradialytic hypotension, muscle cramps, dizziness, nausea, vomiting, and headache.
bp < 0.05, cp < 0.01, vs. baseline by Wilcoxon’s signed-rank test.
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metabolic disorders such as uremia [12-15].
Because serum calcium levels depend on the diffusion 
rate between the dialysate and serum calcium concentra-
tion gradient, special attention is paid to the dialysate cal-
cium level [7,8]. In this study, we investigated the effect of 
reduced dialysate calcium on arterial stiffness parameters 
and serum fetuin-A levels. Our results demonstrated that 
lowering the dialysate calcium concentration, from 1.75 to 
1.5 mmol/L, for 6 months lowered serum total and ionized 
calcium levels significantly and this change was associated 
with definite improvements in central PWV and AIx. With 
the change in serum total calcium, the serum ionized cal-
cium level was reduced, by 15.3%, and central PWV was 
lowered, by 16.7%. Moreover, these changes were accom-
panied by a significant increase in serum fetuin-A levels.
Our results are consistent with previously reported data 
indicating that dialysate calcium directly affects aortic 
stiffness in patients undergoing dialysis. The first descrip-
tion of the relationship in humans was by Marchais et al. 
[16] in 1989. They reported that hemodialysis with a dialy-
sate calcium of 1.75 mmol/L led to a significant increase in 
both central and brachial PWV, but that a concentration of 
1.5 mmol/L did not [16]. Recently, LeBeouf et al. [11] also 
investigated the impact of acute modification of the dialy-
sate calcium level on serum ionized calcium and central 
PWV. Using a crossover study with three different dialy-
sate calcium levels, they found a linear, positive relation-
ship between dialysate calcium concentrations and central 
table 3. Changes in hemodynamic and arterial stiffness parameters over 6 months
Parameters Baseline 2 mon 4 mon 6 mon p valuea
SBP, mmHg
Pre-HD 148 ± 19 149 ± 18 148 ± 18 153 ± 19 0.675
Post-HD 149 ± 20 148 ± 17 147 ± 14 146 ±19 0.924
mAP, mmHg
Pre-HD 100 ± 11 100 ± 12 100 ± 13 103 ± 13 0.741
Post-HD 101 ± 11   99 ± 12 99 ± 9   98 ± 12 0.793
DBP, mmHg
Pre-HD 77 ± 9    76 ± 10   77 ± 13   78 ± 12 0.757
Post-HD 76 ± 8    74 ± 12 75 ± 8 73 ± 9 0.661
PP, mmHg
Pre-HD   72 ± 15    74 ± 14   74 ± 14   71 ± 15 0.532
Post-HD   73 ± 17   74 ± 14   72 ± 13   72 ± 18 0.966
Ba-PWV b, cm/sec 2,043 ± 671 2,057 ± 531 2,038 ± 559 1,939 ± 382 0.578
Hf-PWV b, cm/sec 1,548 ± 450  1,478 ± 275 1,358 ± 345 1,288 ± 345 0.004
AIxb, %   23.3 ± 17.5    16.1 ± 16.9   15.2 ± 14.9   15.2 ± 19.0 0.049
SBP, systolic blood pressure; HD, hemodialysis; MAP, mean arterial pressure; DBP, diastolic blood pressure; PP, pulse pressure; ba-
PWV, brachial-ankle pulse wave velocity; hf-PWV, heart-femoral pulse wave velocity; AIx, augmentation index.
ap value by repeated-measures ANOVA.
bMeasured post-hemodialysis. 
Figure 1. Changes in serum fetuin-A levels after reducing dialy-
sate calcium concentration. The serum fetuin-A level increased 
significantly after 6 months (95.8 ± 45.8 pmol/mL at baseline vs. 
124.9 ± 82.2 pmol/mL at 6 months, p = 0.043).
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PWV, and they suggested that even an acute decrease in 
serum calcium levels from reduced dialysate calcium can 
lead to a detectable improvement in central PWV. A longer 
study was conducted by Demirci et al. [3] with patients 
on peritoneal dialysis. They used higher dialysate calcium 
over 6 months and found a significant worsening of bra-
chial PWV, but the change was not detected with low di-
alysate calcium treatment. These results are similar to our 
data, except that we assessed central PWV, not brachial 
ankle PWV. Although ba-PWV is used as a convenient 
and accurate method to assess central arterial stiffness 
[10], unlike hf-PWV, ba-PWV includes peripheral stiffness 
with the measurements of peripheral artery velocity [17]. 
Generally, the correlation between central and peripheral 
PWV is not definite, suggesting that arterial stiffening 
does not occur equally, especially in patients with renal 
dysfunction. In fact, the increase in PWV is most signifi-
cant in the hf (central) segment compared with the femo-
ral-ankle (peripheral) segment in these patients. Similarly 
in patients with ischemic heart disease (IHD), the positive 
association between IHD and PWV was significant only in 
the hf segment, when an adjustment was made for other 
confounding factors [18]. We thought that because of the 
relatively short duration of our study, only a change in hf-
PWV was observed. However, with longer term follow-up, 
we think that improvement in ba-PWV would also occur.
Several previous studies reported that the serum phos-
phate level decreased with reduced dialysate calcium 
concentrations [19,20]. In contrast to previous studies, the 
serum phosphate level in our patients actually increased, 
from a pretreatment value of 4.8 ± 1.2 to 5.6 ± 1.5 mg/dL at 
6 months after the treatment (p < 0.05). This finding may 
be explained by changes in the phosphate binder. Initially, 
approximately 30% of patients (6/20) used non-calcium-
based phosphate binders, such as sevelamer hydrochloride 
or lanthanum carbonate, which have stronger phosphate-
binding capacity without hypercalcemia. However, as 
serum calcium levels decreased, many of our patients 
changed phosphate binders, to equivalent doses of the 
calcium-based phosphate binder, calcium acetate (PhosLo; 
each dose of sevelamer 800 mg or lanthanum 500 mg was 
changed to calcium acetate 667 mg). Although the dose of 
the calcium-based phosphate binder was similar to that 
of the non-calcium-based phosphate binder, serum phos-
phate levels in our patient group seemed to rise, probably 
due to the lower efficacy of the calcium-based phosphate 
binder. Additionally, five patients received active vitamin 
D treatment after 4 months, which may also have contrib-
uted to the increased serum phosphate level. With those 
five patients, the baseline serum phosphate level was 4.98 
± 1.41 mg/dL, but the level increased to 5.59 ± 1.60 and 5.76 
± 1.75 mg/dL at 4 and 6 months, respectively.
Figure 2. Correlation between ∆serum calcium level and post-dialysis ∆heart-femoral pulse wave velocity (∆hf-PWV) (A) and 
∆fetuin-A (B). Percentage change in serum calcium level was significantly associated with the change in post-dialysis hf-PWV (r = 0.721, 
p < 0.001) and the change in fetuin-A (r = -0.463, p = 0.046).
A B
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Another finding was that the marked improvements in 
arterial stiffness parameters were independent of blood 
pressure. During the study period, despite the use of the 
same doses of antihypertensive drugs, no significant 
change occurred in blood pressure. Systolic, diastolic, 
mean arterial pressure, and pulse pressure remained un-
changed, while the markers of arterial stiffness showed 
significant improvements. These findings somewhat 
contradict those in the report by Argiles et al. [21]. They 
studied the long-term hemodynamic effects of dialysate 
calcium reductions from 1.5 mmol/L to 1.25 mmol/L in 
seven patients for 1 year. At the end of the study, 24-hour 
blood pressure monitoring showed significantly decreased 
diastolic blood pressure and heart rate. These seemingly 
conflicting results are likely due to differences in the base-
line characteristics of the patients. Compared to our study, 
none of their patients had a history of hypertension and 
none received antihypertensive drugs. That the PWV and 
AIx improvements in our study were independent of blood 
pressure may suggest that the decrease in serum calcium 
concentrations affects arterial stiffness by a mechanism 
other than blood pressure control.
Another finding in this study is the significant rise in 
the serum fetuin-A level accompanying the improvement 
in central PWV. Fetuin-A, an abundant serum protein 
produced in the liver, forms calcioprotein particles and 
thereby prevents aggregation of calcium phosphate into 
insoluble mineral crystals [22]. It is also expressed in 
bone, accumulates at sites of vascular calcification, and 
plays a role in skeletal mineralization, possibly through the 
inhibition of calcification [5,23]. In in vitro studies, fetuin-
A contributes about 50% of the calcification-inhibitory 
capacity of human plasma [22]. Recently, several studies 
have reported a protective role of fetuin-A against arterial 
stiffness and cardiovascular mortality in patients with 
ESRD; our results are consistent with these findings [24-
27].
A cohort study of 258 patients with ESRD starting renal 
replacement therapy showed that a low fetuin-A level was 
associated with increased cardiovascular and all-cause 
mortality [25]. Shroff et al. [24] also reported that fetuin-A 
level increased in patients on dialysis compared to healthy 
controls, and that fetuin-A levels were negatively correlat-
ed with dialysis duration, PWV, and vascular calcification. 
In our study, after reducing the level of dialysate calcium, 
serum fetuin-A levels increased significantly and correla-
tion analysis showed a negative association between per-
centage change of serum calcium and fetuin-A levels dur-
ing the whole study period, suggesting a possible role of 
fetuin-A in improving arterial stiffness via upregulation. 
Although our study could not show a significant direct cor-
relation between fetuin-A level and PWV or AIx, this may 
have been due to the small sample size.
Our study had several limitations. The generalizability of 
our findings may be limited because our sample size was 
relatively small and we did not include a control group, 
which may have reduced statistical power. However, to 
minimize the confounding factors, we fixed the medica-
tion list, such as antihypertensive and lipid-lowering 
agents, and controlled dry weight to maintain euvolemic 
status. Although vitamin D treatment in five patients may 
have been a confounding factor, vitamin D analogs were 
used after 4 months in all patients. Thus, improvements 
in PWV and AIx at 2 and 4 months were most likely due to 
reduced dialysate calcium concentrations, and was not a 
vitamin D effect. However, a randomized controlled trial 
with more subjects is necessary, and further long-term 
follow-up is needed to establish the long-term effects of 
lowering the dialysate calcium concentration. 
In conclusion, lowering the dialysate calcium concen-
tration induced a blood pressure-independent, favorable 
effect in arterial stiffness parameters, as indicated by 
improved AIx and central PWV. These findings may be as-
sociated with the upregulation of serum fetuin-A.
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